AAJ0 Stock Overview
Develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Perspective Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$12.20 |
| 52 Week High | US$17.20 |
| 52 Week Low | US$1.99 |
| Beta | 1.47 |
| 11 Month Change | -4.69% |
| 3 Month Change | -6.15% |
| 1 Year Change | 110.34% |
| 33 Year Change | 87.69% |
| 5 Year Change | n/a |
| Change since IPO | -9.63% |
Recent News & Updates
Recent updates
Shareholder Returns
| AAJ0 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | 2.8% | 0.9% |
| 1Y | 110.3% | -14.6% | 5.7% |
Return vs Industry: AAJ0 exceeded the German Biotechs industry which returned -14.6% over the past year.
Return vs Market: AAJ0 exceeded the German Market which returned 5.7% over the past year.
Price Volatility
| AAJ0 volatility | |
|---|---|
| AAJ0 Average Weekly Movement | 12.9% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: AAJ0's share price has been volatile over the past 3 months.
Volatility Over Time: AAJ0's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 118 | Thijs Spoor | www.perspectivetherapeutics.com |
Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans.
Perspective Therapeutics, Inc. Fundamentals Summary
| AAJ0 fundamental statistics | |
|---|---|
| Market cap | €666.83m |
| Earnings (TTM) | -€46.47m |
| Revenue (TTM) | €1.41m |
473.7x
P/S Ratio-14.3x
P/E RatioIs AAJ0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AAJ0 income statement (TTM) | |
|---|---|
| Revenue | US$1.53m |
| Cost of Revenue | US$0 |
| Gross Profit | US$1.53m |
| Other Expenses | US$51.90m |
| Earnings | -US$50.37m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.75 |
| Gross Margin | 100.00% |
| Net Profit Margin | -3,300.98% |
| Debt/Equity Ratio | 0.7% |
How did AAJ0 perform over the long term?
See historical performance and comparison